AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.02 |
Market Cap | 277.64M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.46 |
PE Ratio (ttm) | -6.62 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.06 |
Volume | 1,019,935 |
Avg. Volume (20D) | 1,596,690 |
Open | 3.14 |
Previous Close | 3.11 |
Day's Range | 3.01 - 3.27 |
52-Week Range | 2.24 - 6.23 |
Beta | undefined |
About AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...
Analyst Forecast
According to 8 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 195.57% from the latest price.
Next Earnings Release
Analysts project revenue of $13.13M, reflecting a -0.58% YoY shrinking and earnings per share of -0.13, making a 30.00% increase YoY.
2 months ago · seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call TranscriptAquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sh...